NASDAQ:COGT Cogent Biosciences Q3 2026 Earnings Results & Report $29.58 -1.91 (-6.07%) Closing price 11/5/2026 04:00 PM EasternExtended Trading$29.72 +0.15 (+0.49%) As of 04:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Cogent Biosciences missed analyst earnings expectations in its Q3 2026 results, released November 5, 2026. The company reported EPS of -$0.59 versus the -$0.5573 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 5, 2026TimeBefore Market OpensConference Call12:30 PM ET Cogent Biosciences EPS ResultsActual EPS-$0.59Consensus EPS -$0.5573Beat/MissMissed by -$0.0327One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersCogent Biosciences Revenue ResultsActual RevenueN/AExpected Revenue$750 thousandBeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsCogent Biosciences' Q4 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Cogent Biosciences Q3 2026 Earnings FAQ Did Cogent Biosciences beat earnings estimates for Q3 2026? Cogent Biosciences (NASDAQ:COGT) reported earnings of -$0.59 per share for Q3 2026, missing the consensus estimate of -$0.5573. The report was announced on Thursday, November 5, 2026. When is Cogent Biosciences' next earnings date? Cogent Biosciences' next earnings date is estimated for Monday, November 9, 2026. MarketBeat tracks confirmed and estimated earnings dates for Cogent Biosciences on the company's earnings history page. Cogent Biosciences Earnings HeadlinesCogent Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 5 at 9:28 PM | marketscreener.comMCogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial ResultsNovember 5 at 9:28 PM | finance.yahoo.comGOP wipe out … but here’s WORSE news for the marketA 3 trillion dollar crisis may be building beneath the surface of the stock market, retirement accounts, pensions, and even banks. Reuters reports alarm bells echoing 2007 subprime warnings, and bestselling author Dr. Martin Weiss says this one may already be underway. His free briefing outlines five steps investors are considering to help protect their portfolios. | Weiss Ratings (Ad)Cogent Biosciences (COGT) Projected to Post Quarterly Earnings on FridayOctober 30, 2026 | americanbankingnews.comCogent Biosciences to Participate in the Guggenheim Healthcare Innovation ConferenceOctober 27, 2026 | globenewswire.comCogent Biosciences, Inc. (COGT) - What Are Analysts Thinking About This Stock?October 26, 2026 | americanbankingnews.comSee More Cogent Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cogent Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cogent Biosciences and other key companies, straight to your email. Email Address About Cogent BiosciencesCogent Biosciences (NASDAQ:COGT) is a clinical-stage biotechnology company focused on developing precision medicines for genetically defined diseases. The company uses molecular biology and drug-discovery technologies to design therapies intended to target disease-driving mutations while limiting activity in healthy tissues. Cogent’s lead product candidate is bezuclastinib, also known as CGT9486, an investigational, highly selective inhibitor of the KIT D816V mutation. The company is developing bezuclastinib for systemic mastocytosis, a rare disorder involving the abnormal accumulation of mast cells, including both indolent and advanced forms of the disease. Cogent conducts its research and clinical-development activities primarily in the United States and works with clinical centers and research partners in support of its development programs. The company is headquartered in Boulder, Colorado, and is led by President and Chief Executive Officer Andrew Robbins.View Cogent Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to WatchQualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a CatchUber's Profit Drop: A Speed Bump or Structural Shift?Boeing Has the Orders, the Cash Flow, and Insider Buyers, But What's Still Missing?Keurig Dr Pepper's Beverage Growth Raises a Tough Question About Its Coffee SplitAmazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?Datadog's Post-Earnings Sell-Off: A Buying Opportunity in Plain Sight? Upcoming Earnings Occidental Petroleum (11/9/2026)KKR & Co. Inc. (11/9/2026)Barrick Mining (11/9/2026)Constellation Energy (11/9/2026)Petroleo Brasileiro S.A.- Petrobras (11/10/2026)Transdigm Group (11/10/2026)Honda Motor (11/11/2026)Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
